US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

eXoZymes Inc

10.37

-0.0099-0.10%

Volume:406.00

Turnover:4.21K

Market Cap:86.98M

PE:-10.14

High:10.37

Open:10.37

Low:10.37

Close:10.38

52wk High:23.99

52wk Low:8.86

Shares:8.39M

Float Shares:6.24M

Volume Ratio:0.17

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0223

EPS(LYR):-0.8931

ROE:-940.69%

ROA:-99.79%

PB:16.18

PE(LYR):-11.61

Loading ...

Overview Company News Filings

Exozymes CEO Outlines Biosolutions Growth Strategy in Nasdaq Interview

Exozymes Inc. Reports 99.6% Purity and 90% Yield in 100-Liter NCT Pilot Production Run

Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT

Exozymes Reports Improved Enzyme Performance at Commercial Scale

Exozymes Inc: Files for Offering of up to $50 Mln Mixed Shelf - SEC Filing

THOMSON REUTERS

Exozymes Inc. Touts Breakthrough Enzyme Technology at Beryl Elites Conference

Exozymes CEO Unveils AI-Driven Artificial Evolution for Enzyme Design

Exozymes CEO Joins Beryl Elites Panel on AI in Life Sciences

Exozymes Achieves 99% Conversion in Scaled Cell-Free Biomanufacturing

Slack Capital Calls eXoZymes a Once-in-a-Lifetime Biotech Opportunity

Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology

eXoZymes Inc trading resumes

Exozymes Inc. posts Q3 net loss of $2.29 million

Exozymes Inc. Names Tyler Korman as CSO and Amy Lunzer as Chief of Staff

eXoZymes Inc. - Common Stock Q3 EPS $(0.27)

Exozymes Inc. Highlights AI-Driven Enzyme Innovation in Executive Interview

Exozymes Inc. to Report Third Quarter 2025 Results

Exozymes Inc. CEO Joins AI in Life Sciences Panel at Beryl Elites Investment Conference

eXoZymes Inc trading halted, volatility trading pause

ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EXOZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EXOZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXOZ\",,,,,undefined,":{"symbol":"EXOZ","market":"US","secType":"STK","nameCN":"eXoZymes Inc","latestPrice":10.3701,"timestamp":1770757049275,"preClose":10.38,"halted":0,"volume":406,"delay":0,"changeRate":-0.0009537572254335278,"floatShares":6241972,"shares":8387250,"eps":-1.022266,"marketStatus":"Trading","change":-0.0099,"latestTime":"02-10 15:58:44 EST","open":10.37,"high":10.3701,"low":10.37,"amount":4210.242736,"amplitude":0.00001,"askPrice":10.4,"askSize":55,"bidPrice":10.37,"bidSize":44,"shortable":3,"etf":0,"ttmEps":-1.022266,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"listingDate":1731474000000,"exchange":"NASDAQ","adjPreClose":10.38,"postHourTrading":{"tag":"盘后","latestPrice":10.38,"preClose":10.425,"latestTime":"16:00 EST","volume":16,"amount":166.08,"timestamp":1770670801803,"change":-0.045,"changeRate":-0.004317,"amplitude":0},"volumeRatio":0.174054},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXOZ\",,,,,undefined,":{"symbol":"EXOZ","floatShares":6241972,"roa":"-99.79%","roe":"-940.69%","lyrEps":-0.893053,"volumeRatio":0.174054,"shares":8387250,"dividePrice":0,"high":10.3701,"amplitude":0.00001,"preClose":10.38,"low":10.37,"week52Low":8.86,"pbRate":"16.18","psRate":"-124252.32","week52High":23.99,"institutionHeld":0,"latestPrice":10.3701,"committee":-0.111111,"eps":-1.022266,"divideRate":0,"volume":406,"delay":0,"ttmEps":-1.022266,"open":10.37,"prevYearClose":10.9,"prevWeekClose":10.51,"prevMonthClose":10.4,"prevQuarterClose":10.9,"fiveDayClose":11.25,"twentyDayClose":9.49,"sixtyDayClose":16.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EXOZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"EXOZ","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-08-12","symbol":"EXOZ","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-05-12","symbol":"EXOZ","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2025-03-31","symbol":"EXOZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EXOZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EXOZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EXOZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EXOZ","date":"2026-02-09","current":-10.197933,"percent":0.93871,"low":-38.160378,"twenty":-25.012528,"median":-15.578371,"eighty":-12.345495,"high":-9.544141,"avg":-17.965169,"sd":7.127292,"marketCap":88286711},"quantilePoints":[{"date":"2024-11-15","current":-17.638065,"twenty":-16.673681,"median":-16.303004,"eighty":-13.514057,"marketCap":90376120},{"date":"2024-11-22","current":-27.709046,"twenty":-24.897229,"median":-17.820473,"eighty":-15.786455,"marketCap":141979075},{"date":"2024-11-29","current":-23.431811,"twenty":-26.228751,"median":-23.803745,"eighty":-16.380753,"marketCap":120062842},{"date":"2024-12-06","current":-24.621998,"twenty":-25.324953,"median":-23.431811,"eighty":-17.155873,"marketCap":126161272},{"date":"2024-12-13","current":-28.211156,"twenty":-27.188339,"median":-24.50112,"eighty":-17.856955,"marketCap":144551850},{"date":"2024-12-20","current":-34.534026,"twenty":-28.97362,"median":-25.049722,"eighty":-19.307588,"marketCap":176949760},{"date":"2024-12-27","current":-37.397914,"twenty":-31.565997,"median":-26.072539,"eighty":-21.233684,"marketCap":191624107},{"date":"2025-01-03","current":-27.113953,"twenty":-30.517181,"median":-26.965179,"eighty":-22.844156,"marketCap":138929860},{"date":"2025-01-10","current":-21.20021,"twenty":-29.84785,"median":-26.072539,"eighty":-22.501977,"marketCap":108628285},{"date":"2025-01-17","current":-19.638089,"twenty":-29.457134,"median":-25.39376,"eighty":-20.177393,"marketCap":100624096},{"date":"2025-01-24","current":-25.012528,"twenty":-29.397624,"median":-24.882351,"eighty":-20.355921,"marketCap":128162319},{"date":"2025-01-31","current":-31.168028,"twenty":-29.639419,"median":-25.737799,"eighty":-20.445185,"marketCap":159702637},{"date":"2025-02-07","current":-29.884857,"twenty":-31.406065,"median":-26.053942,"eighty":-20.902663,"marketCap":153127767},{"date":"2025-02-14","current":-36.114743,"twenty":-32.547901,"median":-26.816406,"eighty":-21.058875,"marketCap":185049237},{"date":"2025-02-21","current":-32.934712,"twenty":-32.934712,"median":-27.113953,"eighty":-21.148139,"marketCap":168754994},{"date":"2025-02-28","current":-31.428381,"twenty":-32.934712,"median":-27.625361,"eighty":-21.746952,"marketCap":161036669},{"date":"2025-03-07","current":-26.927986,"twenty":-32.733868,"median":-27.709046,"eighty":-22.345765,"marketCap":137976980},{"date":"2025-03-14","current":-28.545897,"twenty":-32.577656,"median":-27.532377,"eighty":-22.691663,"marketCap":146267033},{"date":"2025-03-21","current":-27.541676,"twenty":-32.551621,"median":-27.541676,"eighty":-22.896227,"marketCap":141121483},{"date":"2025-03-28","current":-18.578079,"twenty":-32.488392,"median":-27.318516,"eighty":-22.691663,"marketCap":95192682},{"date":"2025-04-04","current":-14.204905,"twenty":-32.395408,"median":-26.927986,"eighty":-21.047717,"marketCap":83259709},{"date":"2025-04-11","current":-15.561153,"twenty":-32.347057,"median":-26.881494,"eighty":-20.08069,"marketCap":91209129},{"date":"2025-04-17","current":-15.475495,"twenty":-32.280109,"median":-26.825611,"eighty":-19.083908,"marketCap":90707060},{"date":"2025-04-25","current":-15.318456,"twenty":-32.034633,"median":-26.407279,"eighty":-17.783991,"marketCap":89786601},{"date":"2025-05-02","current":-15.546876,"twenty":-31.65898,"median":-25.988854,"eighty":-16.786058,"marketCap":91125450},{"date":"2025-05-09","current":-18.573449,"twenty":-31.439539,"median":-25.049722,"eighty":-16.354836,"marketCap":108865208},{"date":"2025-05-16","current":-18.757829,"twenty":-31.32424,"median":-24.714982,"eighty":-16.354836,"marketCap":125851862},{"date":"2025-05-23","current":-18.209062,"twenty":-30.974622,"median":-24.436031,"eighty":-16.569406,"marketCap":122170026},{"date":"2025-05-30","current":-17.336025,"twenty":-30.684514,"median":-24.380241,"eighty":-16.780348,"marketCap":116312559},{"date":"2025-06-06","current":-17.061642,"twenty":-30.529046,"median":-23.441109,"eighty":-16.780348,"marketCap":114471640},{"date":"2025-06-13","current":-16.400628,"twenty":-29.90271,"median":-22.948297,"eighty":-16.721282,"marketCap":110036701},{"date":"2025-06-20","current":-15.402871,"twenty":-29.884857,"median":-22.501977,"eighty":-16.400628,"marketCap":103342453},{"date":"2025-06-27","current":-12.12948,"twenty":-29.84785,"median":-21.135121,"eighty":-16.003718,"marketCap":81380299},{"date":"2025-07-03","current":-12.359713,"twenty":-29.639419,"median":-20.735293,"eighty":-15.802318,"marketCap":82924997},{"date":"2025-07-11","current":-12.496904,"twenty":-29.483169,"median":-20.177393,"eighty":-15.6911,"marketCap":83845456},{"date":"2025-07-18","current":-11.536563,"twenty":-29.397624,"median":-19.545105,"eighty":-15.486916,"marketCap":77402242},{"date":"2025-07-25","current":-12.409601,"twenty":-29.129833,"median":-18.888784,"eighty":-15.347008,"marketCap":83259709},{"date":"2025-08-01","current":-12.59668,"twenty":-29.036849,"median":-18.782773,"eighty":-15.15285,"marketCap":84514881},{"date":"2025-08-08","current":-12.484432,"twenty":-28.955024,"median":-18.583221,"eighty":-14.399063,"marketCap":83761778},{"date":"2025-08-15","current":-10.86886,"twenty":-28.847163,"median":-18.391255,"eighty":-12.940906,"marketCap":83788627},{"date":"2025-08-22","current":-10.129037,"twenty":-28.601687,"median":-18.146703,"eighty":-12.680718,"marketCap":78085297},{"date":"2025-08-29","current":-10.553347,"twenty":-28.278104,"median":-17.797382,"eighty":-12.592988,"marketCap":81356325},{"date":"2025-09-05","current":-11.505325,"twenty":-28.18884,"median":-17.655417,"eighty":-12.491915,"marketCap":88695168},{"date":"2025-09-12","current":-13.490877,"twenty":-28.107015,"median":-17.448273,"eighty":-12.538062,"marketCap":104001900},{"date":"2025-09-19","current":-14.959642,"twenty":-27.850381,"median":-17.370635,"eighty":-12.573133,"marketCap":115324687},{"date":"2025-09-26","current":-15.847102,"twenty":-27.608624,"median":-17.061642,"eighty":-12.589297,"marketCap":122166167},{"date":"2025-10-03","current":-14.479193,"twenty":-27.541676,"median":-16.87379,"eighty":-12.59668,"marketCap":111620877},{"date":"2025-10-10","current":-14.687648,"twenty":-27.530518,"median":-16.831742,"eighty":-12.611646,"marketCap":113227875},{"date":"2025-10-17","current":-13.708472,"twenty":-27.277603,"median":-16.76567,"eighty":-12.63659,"marketCap":105679350},{"date":"2025-10-24","current":-13.055688,"twenty":-27.024689,"median":-16.432585,"eighty":-12.67218,"marketCap":100647000},{"date":"2025-10-31","current":-13.758627,"twenty":-26.942863,"median":-16.351816,"eighty":-12.69627,"marketCap":106066002},{"date":"2025-11-07","current":-14.687648,"twenty":-26.927986,"median":-16.160757,"eighty":-12.7049,"marketCap":113227875},{"date":"2025-11-14","current":-17.842773,"twenty":-26.927986,"median":-16.281848,"eighty":-12.745787,"marketCap":137550900},{"date":"2025-11-21","current":-15.99071,"twenty":-26.872196,"median":-16.260691,"eighty":-12.78526,"marketCap":133357275},{"date":"2025-11-28","current":-15.960539,"twenty":-26.834928,"median":-16.09128,"eighty":-12.82517,"marketCap":133105657},{"date":"2025-12-05","current":-15.085575,"twenty":-26.827452,"median":-15.997214,"eighty":-12.905985,"marketCap":125808750},{"date":"2025-12-12","current":-15.99071,"twenty":-26.816406,"median":-15.99071,"eighty":-12.979888,"marketCap":133357275},{"date":"2025-12-19","current":-12.269601,"twenty":-26.652755,"median":-15.960539,"eighty":-12.82517,"marketCap":102324450},{"date":"2025-12-26","current":-12.541142,"twenty":-26.340331,"median":-15.88442,"eighty":-12.702264,"marketCap":104589007},{"date":"2026-01-02","current":-10.962185,"twenty":-26.072539,"median":-15.879825,"eighty":-12.621624,"marketCap":91421025},{"date":"2026-01-09","current":-9.735225,"twenty":-26.035346,"median":-15.826918,"eighty":-12.591427,"marketCap":81188580},{"date":"2026-01-16","current":-10.831443,"twenty":-25.942362,"median":-15.72345,"eighty":-12.541142,"marketCap":90330682},{"date":"2026-01-23","current":-11.684272,"twenty":-25.778712,"median":-15.703916,"eighty":-12.481938,"marketCap":97442992},{"date":"2026-01-30","current":-10.264028,"twenty":-25.187337,"median":-15.697179,"eighty":-12.393387,"marketCap":85598629},{"date":"2026-02-06","current":-10.928823,"twenty":-25.019967,"median":-15.609105,"eighty":-12.356869,"marketCap":91142799},{"date":"2026-02-09","current":-10.586353,"twenty":-25.012528,"median":-15.578371,"eighty":-12.345495,"marketCap":88286711}],"updateTime":1770734070421},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EXOZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609858794","title":"Exozymes CEO Outlines Biosolutions Growth Strategy in Nasdaq Interview","url":"https://stock-news.laohu8.com/highlight/detail?id=2609858794","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609858794?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:52","pubTimestamp":1770328378,"startTime":"0","endTime":"0","summary":"Michael Heltzen, CEO of eXoZymes Inc. , recently discussed the company's innovative approach and future plans in an interview as part of Nasdaq's 'Amplify Spotlight' series. Heltzen outlined how eXoZymes develops biosolutions for valuable natural products and their pharmaceutical counterparts, leveraging a foundational science breakthrough that the company was built and IPO'd on last year. He highlighted the firm's alternative financing route and the opportunities it brings for investor engagement and company growth. Looking ahead, Heltzen defined success for eXoZymes as the application of its breakthrough technology across multiple markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content use","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL7qGN3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"gpt_icon":0},{"id":"2609762893","title":"Exozymes Inc. Reports 99.6% Purity and 90% Yield in 100-Liter NCT Pilot Production Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2609762893","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609762893?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:04","pubTimestamp":1770289476,"startTime":"0","endTime":"0","summary":"eXoZymes Inc. announced the results of its recent 100-liter pilot production run of NCT, a process carried out in collaboration with Cayman Chemical. The company reported achieving approximately 99% reaction conversion, 91% process recovery, and a 90% isolated yield, resulting in 535 grams of isolated NCT. The final product purity was measured at 99.6% based on post-isolation analytical characterization. This marks the first time the exozyme-based biomanufacturing process has been run end-to-end by an external partner, demonstrating protocol transferability and operational robustness. High-purity NCT is now available for formulation development with commercial partners, and eXoZymes is engaging with interested companies for product validation and application-specific testing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL5TH3K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2607063684","title":"Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT","url":"https://stock-news.laohu8.com/highlight/detail?id=2607063684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607063684?lang=en_us&edition=fundamental","pubTime":"2026-01-30 08:45","pubTimestamp":1769733913,"startTime":"0","endTime":"0","summary":"Exozymes Inc. has announced detailed results from a 100-liter pilot production run of N-trans-caffeoyltyramine  using its AI-enhanced enzymes, known as exozymes. The pilot, executed by Cayman Chemical as an independent external partner, demonstrated improved reaction performance at larger scales, achieving approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity. These findings support the scalability and robustness of Exozymes' biomanufacturing process, with high-purity NCT now available for formulation development with commercial partners. The results have already been reported by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original conten","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL4qTvP6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2607068043","title":"Exozymes Reports Improved Enzyme Performance at Commercial Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2607068043","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607068043?lang=en_us&edition=fundamental","pubTime":"2026-01-30 08:38","pubTimestamp":1769733490,"startTime":"0","endTime":"0","summary":"Exozymes Inc. has announced new scientific research results from its 100-liter pilot production run of NCT, utilizing its AI-enhanced enzymes, known as exozymes. According to the company, performance of the cell-free biomanufacturing process improved as the reaction scale increased, with higher recovery, isolated yield, and pharmaceutical-grade purity achieved at larger volumes. The pilot run, independently executed by Cayman Chemical using a technology transfer package from Exozymes, marks the first full end-to-end operation of the exozyme-based process by an external partner, demonstrating both protocol transferability and operational robustness. These results have been reported and expand upon previously announced scale-up milestones, with high-purity NCT now available for commercial formulation development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL58JMP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2604916246","title":"Exozymes Inc: Files for Offering of up to $50 Mln Mixed Shelf - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2604916246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604916246?lang=en_us&edition=fundamental","pubTime":"2026-01-17 04:48","pubTimestamp":1768596510,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nFWN3YH1HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EXOZ"],"gpt_icon":0},{"id":"2601987983","title":"Exozymes Inc. Touts Breakthrough Enzyme Technology at Beryl Elites Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601987983","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601987983?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:44","pubTimestamp":1767883474,"startTime":"0","endTime":"0","summary":"Exozymes Inc.'s Capital Markets Advisor, Sanjeev Srivastava, spoke at the Beryl Elites' Investment Conference in New York City, highlighting a pivotal shift in biomanufacturing. Srivastava compared the industry’s advancements to a “ChatGPT moment,” emphasizing eXoZymes’ breakthrough technology that enables enzymes to function outside of cells. He explained that this innovation allows for the cost-effective and unprecedented production of medicines, nutraceuticals, and chemicals that were previously unattainable through natural processes, marking an exciting development for the sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on January 08, 2026, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDLyWttk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2601180281","title":"Exozymes CEO Unveils AI-Driven Artificial Evolution for Enzyme Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2601180281","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601180281?lang=en_us&edition=fundamental","pubTime":"2026-01-07 23:37","pubTimestamp":1767800272,"startTime":"0","endTime":"0","summary":"Exozymes Inc. CEO Michael Heltzen was recently interviewed by Maxine Hoover from The Beryl Consulting Group at the Beryl Elites' Investment Conference in New York City. During the discussion, Heltzen described the company's approach to \"Artificial Evolution,\" explaining how advanced AI algorithms now allow the company to predict the effects of DNA changes on enzyme structure and function. This capability enables Exozymes to design and create new chemical reactions, making it possible to develop natural products and drug candidates that were previously considered unattainable.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on January 07, 2026, and is solely re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2Zk3Hb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2591647716","title":"Exozymes CEO Joins Beryl Elites Panel on AI in Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647716","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647716?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:09","pubTimestamp":1765811366,"startTime":"0","endTime":"0","summary":"Exozymes Inc. participated in the Beryl Elites' 7th Annual Investment Conference on November 4, 2025, in New York City. CEO Michael Heltzen was featured as a panelist in the discussion titled \"AI's Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact.\" Heltzen highlighted Exozymes' focus on leveraging AI to create new chemistries in drug discovery and development, aiming to generate competitive advantages and tangible impacts in the life sciences sector. The panel explored how machine learning is driving breakthroughs in biopharma, showcasing real-world applications and addressing industry challenges.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2Wk2zg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2590295549","title":"Exozymes Achieves 99% Conversion in Scaled Cell-Free Biomanufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590295549","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590295549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:10","pubTimestamp":1765487421,"startTime":"0","endTime":"0","summary":"Exozymes Inc. has announced significant scientific research results demonstrating that their exozyme biosolution achieved over 99% conversion at scale, marking a major advancement in cell-free enzyme production pathways. This outcome supports the potential of exozymes to overcome key limitations of traditional biomanufacturing approaches. The company, together with Cayman Chemical, is currently analyzing data and working on the isolation process for NCT. Additional technical details are expected to be published in a subsequent press release following completion of downstream analysis and NCT extraction, with further information not anticipated until early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL19X8Bm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2584940814","title":"Slack Capital Calls eXoZymes a Once-in-a-Lifetime Biotech Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2584940814","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584940814?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:49","pubTimestamp":1763563752,"startTime":"0","endTime":"0","summary":"Slack Capital has released an independent investment research report on Exozymes Inc., describing the company as a \"once-in-a-lifetime opportunity.\" The report highlights Exozymes' recent Q3 investor call as a significant turning point, praising management's clear roadmap for near-term revenues and disciplined strategy for shareholder value. Slack Capital's analysis maintains an extremely bullish outlook, emphasizing a compelling risk-reward profile for investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLnmPKl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"gpt_icon":0},{"id":"2584663069","title":"Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2584663069","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584663069?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:26","pubTimestamp":1763501206,"startTime":"0","endTime":"0","summary":"Michael Heltzen, CEO of eXoZymes Inc., was recently interviewed by Lou Basenese on episode #2 of \"The Upside.\" During the interview, Heltzen detailed the company's breakthrough in translating cell-free enzymatic pathway technology from the lab to new product lines already reaching the market. He emphasized that eXoZymes is currently the only company able to run entire enzymatic pathways outside of cells, distinguishing its platform from competitors. The discussion also touched on the challenges of synthetic biology and the company's accelerating innovation in creating new-to-nature molecules with significant pharmaceutical potential. The URL for the full speech/interview was not provided in the document.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLY01Tv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139","CLDX"],"gpt_icon":0},{"id":"2584543269","title":"eXoZymes Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2584543269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584543269?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:35","pubTimestamp":1763483749,"startTime":"0","endTime":"0","summary":"11:32 EST eXoZymes (EXOZ) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exozymes-inc-trading-resumes-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exozymes-inc-trading-resumes-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EXOZ"],"gpt_icon":0},{"id":"2583439512","title":"Exozymes Inc. posts Q3 net loss of $2.29 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583439512","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583439512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:30","pubTimestamp":1763069427,"startTime":"0","endTime":"0","summary":"Exozymes Inc. reported a net loss of $2.3 million for the third quarter of 2025, with a year-to-date loss of $6.5 million. Operating expenses increased by $0.9 million compared to the prior year, mainly due to expanded research and development and new leadership hires. The company ended the second quarter of 2025 with $5.1 million in cash and cash equivalents, supporting operations into early Q2 2026. Business developments during the period included progress by its subsidiary NCTx on an exploratory analog program and ongoing development of assets for santalene and non-intoxicating cannabinoids. Exozymes also appointed Amy Lunzer as Chief of Staff and named co-founder Tyler Korman as Chief Scientific Officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL8JRDzV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"gpt_icon":0},{"id":"2583514048","title":"Exozymes Inc. Names Tyler Korman as CSO and Amy Lunzer as Chief of Staff","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514048","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514048?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:18","pubTimestamp":1763068738,"startTime":"0","endTime":"0","summary":"Exozymes Inc. has announced new management appointments. Tyler Korman, PhD, co-founder of the company, is now serving as Chief Scientific Officer. Amy Lunzer has been named Chief of Staff. These changes are effective immediately.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL1JbN3p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2583141565","title":"eXoZymes Inc. - Common Stock Q3 EPS $(0.27)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583141565","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583141565?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:10","pubTimestamp":1763068243,"startTime":"0","endTime":"0","summary":"eXoZymes Inc. - Common Stock Q3 EPS $(0.27)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48850312/exozymes-inc-common-stock-q3-eps-0-27","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"eXoZymes Inc. - Common Stock Q3 EPS $(0.27)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ"],"gpt_icon":0},{"id":"2582839136","title":"Exozymes Inc. Highlights AI-Driven Enzyme Innovation in Executive Interview","url":"https://stock-news.laohu8.com/highlight/detail?id=2582839136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582839136?lang=en_us&edition=fundamental","pubTime":"2025-11-12 02:48","pubTimestamp":1762886902,"startTime":"0","endTime":"0","summary":"Exozymes Inc.'s co-founder and VP of Research, Dr. Tyler Korman, recently discussed the company's unique approach to leveraging AI in enzyme development. Dr. Korman emphasized the critical role of proprietary enzyme data generation in optimizing exozymes for cell-free environments. By harnessing AI and large language models, Exozymes can rapidly design, build, and test more functional enzymes tailored for biomanufacturing and biocatalysis applications. He highlighted the company's \"secret power\" as its ability to directly measure enzyme functions, providing essential data to refine AI models and accelerate innovation in creating new molecules for pharmaceuticals, nutraceuticals, and specialty chemicals. No URL for the full speech or interview was provided in the document.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL6NbbL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"gpt_icon":0},{"id":"2582385589","title":"Exozymes Inc. to Report Third Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582385589","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582385589?lang=en_us&edition=fundamental","pubTime":"2025-11-11 06:00","pubTimestamp":1762812018,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL3zMCyk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"gpt_icon":0},{"id":"2579214174","title":"Exozymes Inc. CEO Joins AI in Life Sciences Panel at Beryl Elites Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2579214174","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579214174?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:11","pubTimestamp":1761855099,"startTime":"0","endTime":"0","summary":"Exozymes Inc. CEO Michael Heltzen will speak at the Beryl Elites' 7th Annual Investment Conference in New York City on November 4, 2025. He will join the panel \"AI's Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact,\" where he will present Exozymes' next-generation biomanufacturing platform that uses AI to engineer cell-free enzymes for producing valuable natural products, including their flagship metabolism-boosting molecule, NCT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLCkVGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2577543923","title":"eXoZymes Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2577543923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577543923?lang=en_us&edition=fundamental","pubTime":"2025-10-24 23:30","pubTimestamp":1761319820,"startTime":"0","endTime":"0","summary":"11:25 EDT eXoZymes (EXOZ) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exozymes-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exozymes-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXOZ","BK4139"],"gpt_icon":0},{"id":"2572523484","title":"ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview","url":"https://stock-news.laohu8.com/highlight/detail?id=2572523484","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572523484?lang=en_us&edition=fundamental","pubTime":"2025-10-03 04:45","pubTimestamp":1759437943,"startTime":"0","endTime":"0","summary":"Exozymes Inc. CEO Michael Heltzen recently spoke on the Inside Biotech podcast, sharing the company's innovative approach to chemical manufacturing by \"liberating enzymes from cells\" and leveraging AI-powered enzyme evolution. Heltzen highlighted Exozymes' rapid six-week development timelines, their bold IPO strategy amid challenging biotech markets, and the potential for sustainable, scalable enzyme-based production to transform pharmaceuticals and beyond. The interview offers insights into Exozymes' mission, technology, and future vision for synthetic biology. The full podcast episode is available at: SimplecastApple PodcastSpotify . Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDLbmG7Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}